Solventum had its Relative Strength (RS) Rating upgraded from 62 to 72 Tuesday — a welcome improvement, but still below the 80 or higher score you prefer to see.
IBD's proprietary RS Rating tracks technical performance by using a 1 (worst) to 99 (best) score that indicates how a stock's price performance over the trailing 52 weeks matched up against all other stocks.
History shows that the best stocks typically have an RS Rating north of 80 in the early stages of their moves. See if Solventum can continue to rebound and clear that threshold.
When To Sell Stocks To Lock In Profits And Minimize Losses
Solventum is trying to complete a consolidation with a 77.17 buy point. See if the stock can clear the breakout price in volume at least 40% above average.
Solventum posted -43% earnings growth in the latest quarterly report, while sales growth came in at 0%.
Solventum earns the No. 46 rank among its peers in the Medical-Products industry group. Globus Medical, Pro-Dex and Insulet are among the top 5 highly rated stocks within the group.
RELATED:
IBD Stock Rating Upgrades: Rising Relative Strength
Why Should You Use IBD's Relative Strength Rating?
How Relative Strength Line Can Help You Judge A Stock
Ready To Grow Your Investing Skills? Join An IBD Meetup Group!
